Table 1 Targeted agents and clinical trials related to monoclonal antibodies
Drug | Disease | Trial name | Phase | Status | ORR/CR | NCT# | Reference |
|---|---|---|---|---|---|---|---|
Anti-CD20 antibody | |||||||
Ofatumumab | A fully humanized second-generation type I CD20 antibody | ||||||
Ofatumumab, fludarabine, cyclophosphamide | CLL | Ofatumumab with fludarabine and cyclophosphamide in b-cell chronic lymphocytic leukemia patients | 2 | Completed | 500 mg, 77%/42%; 100 mg, 73%/50% | NCT00410163 | |
Obinutuzumab | A humanized type II CD20 antibody | ||||||
Obinutuzumab | Relapsed or refractory DLBCL/MCL | A dose-escalating study of obinutuzumab in patients with b-lymphocyte antigen (CD20+) malignant disease (gauguin) | 1/2 | Completed | DLBCL, 28%/4%; MCL, 27%/13% | NCT00517530 | |
Obinutuzumab, bendamustine vs. bendamustine | Rituximab-refractory iNHLs | A study to investigate the efficacy and safety of bendamustine compared with bendamustine plus obinutuzumab in participants with rituximab-refractory, indolent non-Hodgkin’s lymphoma (GADOLIN) | 3 | Completed | Obinutuzumab plus bendamustine, 69%/11%; bendamustine monotherapy, 63%/12% | NCT01059630 | |
Obinutuzumab, CHOP/CVP/bendamustine vs. rituximab, CHOP/CVP/bendamustine | Untreated iNHLs | A study of obinutuzumab (RO5072759) plus chemotherapy in comparison with rituximab plus chemotherapy followed by obinutuzumab or rituximab maintenance in patients with untreated advanced indolent non-Hodgkin’s lymphoma (GALLIUM) | 3 | Active, not recruiting | FL: obinutuzumab group, 88.5%/19.5%; rituximab group, 86.9%/23.8% | NCT01332968 | |
Obinutuzumab, CHOP/FC/bendamustine | FL | A study of obinutuzumab in combination with chemotherapy in participants with CD20+ B-cell follicular non-Hodgkin’s lymphoma | 1 | Completed | G-CHOP, 96%/39%; G-FC, 93%/50% | NCT00825149 | |
G-Clb vs. Clb vs. R-Clb | Untreated CLL | CLL11: a study of obinutuzumab with chlorambucil in patients with previously untreated chronic lymphocytic leukemia (Stage 1a) | 3 | Completed | G-Clb, 77.3%/22.3%; Clb, 31.4%/0%; R-Clb, 65.7%/7.3% | NCT01010061 | |
Obinutuzumab, ibrutinib vs. obinutuzumab, chlorambucil | Untreated CLL/SLL | A multicenter study of ibrutinib in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab in patients with treatment naïve CLL or SLL | 3 | Completed | Obinutuzumab plus ibrutinib, 91%/41%; obinutuzumab plus chlorambucil, 81%/16% | NCT02264574 | |
Ublituximab | A type I, chimeric, recombinant IgG1 monoclonal antibody targeting a unique epitope on the CD20 antigen, glycoengineered to enhance affinity for all FcRIIIa variants | ||||||
Ublituximab, ibrutinib | CLL/MCL | Ublituximab plus ibrutinib in select B-cell malignancies | 1/2 | Completed | 88%/5% | NCT02013128 | |
Ublituximab, ibrutinib vs. ibrutinib | Previously treated high-risk CLL | Ublituximab in combination with ibrutinib versus ibrutinib alone in patients with previously treated high-risk chronic lymphocytic leukemia | 3 | Active, not recruiting | combination arm, 78%/7%; monotherapy, 45%/0% | NCT02301156 | |
Ublituximab, umbralisib vs. obinutuzumab, chlorambucil | CLL | Ublituximab plus umbralisib compared to obinutuzumab plus chlorambucil in patients with untreated and previously treated chronic lymphocytic leukemia | 3 | Active, not recruiting | – | NCT02612311 | – |
Ublituximab, umbralisib; ublituximab, umbralisib, ibrutinib | B-NHLs, CLL | Ublituximab in combination with umbralisib +/− ibrutinib or bendamustine in patients with B-cell malignancies | 1 | Completed | Ublituximab, umbralisib, ibrutinib, 84%/30%; ublituximab, umbralisib, 46%/17% | NCT02006485 | |
Veltuzumab | A humanized type I anti-CD20 monoclonal antibody | ||||||
Veltuzumab | Relapsed or refractory B-NHLs | Study of humanized anti-CD20 in patients with CD20+ non-Hodgkin’s lymphoma | 1/2 | Completed | FL, 44%/27%; MZL, 83%/33%; DLBCL, 43%/0% | NCT00285428 | |
Ocrelizumab | A humanized type I anti-CD20 monoclonal antibody | ||||||
Ocrelizumab | Relapsed or refractory FL | An open-label, multicentre, dose-escalating phase 1/2 trial of 3-weekly ocrelizumab in patients with follicular non-Hodgkin’s lymphoma | 1/2 | Completed | 38%/15% | NCT02723071 | |
CT-P10 | A rituximab biosimilar | ||||||
CT-P10 vs. rituximab | FL | To compare efficacy and safety between CT-P10 and rituxan in patients with low tumor burden follicular lymphoma | 3 | Active, not recruiting | CT-P10, 83%/28%; rituximab, 81%/34% | NCT02260804 | |
CT-P10, CVP vs. R-CVP | FL | To demonstrate equivalence of pharmacokinetics and noninferiority of efficacy for CT-P10 in comparison with rituxan | 3 | Completed | CT-P10, CVP, 97%/30%; R-CVP, 93%/22% | NCT02162771 | |
GP2013 | A rituximab biosimilar | ||||||
GP2013, CVP vs. R-CVP | Untreated advanced-stage FL | GP2013 in The treatment of patients with previously untreated, advanced-stage follicular lymphoma | 3 | Completed | GP2013, CVP, 87%/15%; R-CVP, 88%/13% | NCT01419665 | |
PF-05280586 | A rituximab biosimilar | ||||||
PF-05280586 vs.rituximab | FL | A study of PF-05280586 (Rituximab-Pfizer) or MabThera® (Rituximab-EU) for the First-Line treatment of patients with CD20+, low tumor burden, follicular lymphoma (REFLECTIONS B328-06) | 3 | Completed | PF-05280586, 76%/26%; rituximab, 71%/28% | NCT02213263 | |
ABP798 | A rituximab biosimilar | ||||||
ABP798 vs. rituximab | B-NHLs | Study to assess if ABP798 Is safe and effective in treating non-Hodgkin’s lymphoma compared to rituximab | 3 | completed | NA | NCT02747043 | – |
90Y-ibritumomab tiuxetan | A radiolabeled anti-CD20 monoclonal antibody which targets the same epitope on the CD20 molecule like rituximab and chelates the radioactive particle Yttrium-90 | ||||||
90Y-ibritumomab tiuxetan | FL | 90Y-Ibritumomab tiuxetan first line in follicular lymphoma | 2 | Unknown status | 87%/56% | NCT00772655 | |
90Y-ibritumomab tiuxetan | FL | Phase 2 study of fractionated 90Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma | 2 | Completed | 95.8%/69.4% | NCT01493479 | |
90Y-ibritumomab tiuxetan vs. no treatment | FL | Treatment with 90Y-ibritumomab tiuxetan versus no treatment in patients with follicular non-Hodgkin’s lymphoma (stage III or IV) having achieved a partial or complete pemission after first line chemotherapy | 3 | Completed | PR after induction therapy converted to a CR/CRu: consolidation arm, 77%; control arm, 17.5% | NCT00185393 | |
90Y-ibritumomab tiuxetan, rituximab vs. rituximab | Untreated FL | Rituximab with or without 90Y-Ibritumomab tiuxetan in treating patients with untreated follicular lymphoma | 3 | Recruiting | – | NCT02320292 | – |
90Y-ibritumomab tiuxetan vs. ASCT | Relapsed or refractory FL | A phase 3 multicenter, randomized study comparing 90Y-Ibritumomab tiuxetan vs. ASCT in patients with relapsed or refractory FL | 3 | Recruiting | – | NCT01827605 | – |
90Y-ibritumomab tiuxetan, BEAM | FL/DLBCL/MCL/transformed lymphomas | Phase 2 trial of a transplantation regimen of 90Y-Ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin’s lymphoma | 2 | Completed | NA | NA | |
Anti-CD22 antibody | |||||||
Epratuzumab | A humanized IgG1 monoclonal antibody targeting CD22 | ||||||
Epratuzumab | Relapsed or refractory iNHLs | Phase 1/2 trial of epratuzumab in indolent non-Hodgkin’s lymphoma | 1/2 | Completed | all, 18%/6%; FL, 24%/8% | NA | |
Epratuzumab | Relapsed or refractory aggressive NHLs | Phase 1/2 trial of epratuzumab in patients with recurrent aggressive NHLs | 1/2 | Completed | all, 10%/6%; DLBCL, 15%/9% | NA | |
Epratuzumab, rituximab | Relapsed or refractory iNHLs | Phase 2 trial of rituximab plus epratuzumab in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma | 2 | Completed | FL, 54%/24%; SLL, 57%/43% | NA | |
Epratuzumab, rituximab | Untreated FL | Epratuzumab and rituximab in treating patients with previously untreated follicular non-Hodgkin’s lymphoma | 2 | Completed | 88.2%/42.4% | NCT00553501 | |
Epratuzumab, R-CHOP | DLBCL | Monoclonal antibody therapy and combination chemotherapy in treating patients with stage II, stage III, or stage IV diffuse large B-cell lymphoma | 2 | Completed | 96%/74% | NCT00301821 | |
Inotuzumab | A CD22-targeted ADC combining a humanized IgG4 anti-CD22 monoclonal antibody with calicheamicin, an enediyne antibiotic | ||||||
Inotuzumab ozogamicin, rituximab | B-NHLs | Study evaluating inotuzumab ozogamicin administered in combination with rituximab in subjects with non-Hodgkin’s lymphoma | 1/2 | Completed | Relapsed FL, 87%/62%; relapsed DLBCL, 74%/50%; refractory aggressive NHLs, 20%/3% | NCT00299494 | |
R-InO vs. RB/RG | Relapsed or refractory aggressive NHLs | A study of inotuzumab ozogamicin plus rituximab for relapsed or refractory aggressive non-Hodgkin’s lymphoma patients who are not candidates for intensive high-dose chemotherapy | 3 | Terminated | R-InO, 41%/13%; RB/RG, 44%/13%; | NCT01232556 | |
Inotuzumab ozogamicin, R-CVP vs. R-G-CVP | DLBCL | Treatment of patients with diffuse large B-cell lymphoma who are not suitable for anthracycline containing chemotherapy | 2 | Active, not recruiting | – | NCT01679119 | – |
Moxetumomab pasudotox | A recombinant immunotoxin consisting of the Fv portion of the anti-CD22 antibody and a fragment of pseudomonas exotoxin A | ||||||
Moxetumomab pasudotox | Relapsed or refractory HCL | Safety study of moxetumomab pasudotox in patients with HCL with advance disease | 1 | Unknown | 86%/46% | NCT00462189 | |
Moxetumomab pasudotox | Relapsed or refractory HCL | Moxetumomab pasudotox for advanced HCL | 3 | Completed | 75%/41% | NCT01829711 | |
Anti-CD30 antibody | |||||||
SGN-30 | A chimeric monoclonal antibody consisting of the variable region of an anti-CD30 murine monoclonal antibody with human gamma 1 heavy chain and kappa light chain constant regions | ||||||
SGN-30 | Relapsed or refractory HL/ALCL | Phase 2 study of SGN-30 in Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma | 2 | Completed | ALCL, 17%/5%; HL, 0%/0% | NA | |
SGN-30, GVD vs. placebo, GVD | Relapsed or refractory classical HL | Phase 2 trial of SGN-30 or placebo with GVD in patients with relapsed or refractory classical HL | 2 | Terminated | SGN-30, GVD, 65%/NA; GVD, 57%/NA | NA | |
BV | A CD30 ADC connecting an anti-CD30 antibody with the anti-mitotic agent MMAE via a valine-citrulline peptide linker | ||||||
BV | HL/ALCL | Phase 1 open-label dose finding study of brentuximab vedotin for CD30+ hematologic malignancies | 1 | Completed | 38%/27% | NCT00430846 | |
BV | HL | A pivotal open-label Trial of brentuximab vedotin for Hodgkin’s lymphoma | 2 | Completed | 75%/34% | NCT00848926 | |
BV | ALCL | A phase 2 open-label trial of brentuximab vedotin for systemic anaplastic large cell lymphoma | 2 | Completed | 86%/57% | NCT00866047 | |
BV | Relapsed or refractory NHLs | A study of brentuximab vedotin in relapsed or refractory non-Hodgkin’s lymphoma | 2 | Completed | T-NHLs, 41%/24% | NCT01421667 | |
BV vs. methotrexate/bexarotene | CD30+ CTCL | A phase 3 trial of brentuximab vedotin versus physician’s choice (methotrexate or bexarotene) in participants with CD30+ cutaneous T-cell lymphoma (ALCANZA study) | 3 | Completed | BV, 56%/16%; methotrexate/bexarotene, 13%/2% | NCT01578499 | |
BV, AVD vs. ABVD | Advanced classical HL | A frontline therapy trial in participants with advanced classical Hodgkin’s lymphoma | 3 | Active, not recruiting | A+AVD, 86%/73%; ABVD, 83%/70% | NCT01712490 | |
BV, CHP, CHOP | CD30+ mature T-cell and NK-cell neoplasms | A phase 1 study of brentuximab vedotin given sequentially and combined with multi-agent chemotherapy for CD30+ mature T-cell and NK-cell neoplasms | 1 | Completed | sequential treatment, 85%/62%; combination treatment, 100%/88% | NCT01309789 | |
BV, CHP vs. CHOP | CD30+ mature T-cell lymphomas | ECHELON-2: A comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30+ mature T-cell lymphomas | 3 | Active, not recruiting | BV, CHP, 83%/68%; CHOP, 72%/56% | NCT01777152 | |
Anti-CD52 antibody | |||||||
Alemtuzumab | A humanized monoclonal antibody targeting CD52 | ||||||
Alemtuzumab | Relapsed or refractory CLL | Phase 2 trial of slemtuzumab in patients with relapsed or refractory B-cell chronic lymphocytic leukemia exposed to alkylating agents and having failed fludarabine therapy | 2 | Completed | 33%/2% | NA | |
Alemtuzumab vs. chlorambucil | CLL | A phase 3 study to evaluate the efficacy and safety of frontline therapy with alemtuzumab vs. chlorambucil in patients with progressive B-cell chronic lymphocytic leukemia | 3 | Completed | Alemtuzumab, 83%/24%; chlorambucil, 55%/2% | NA | |
Alemtuzumab | Advanced MF/SS | Phase 2 study of alemtuzumab in patients with advanced mycosis fungoides/Sézary syndrome | 2 | Completed | 55%/32% | NA | |
Alemtuzumab | Relapsed or refractory PTCL | A pilot study of alemtuzumab therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma | 2 | Completed | 36%/21% | NA | |
Alemtuzumab, FC vs. FCR | CLL | Fludarabine, cyclophosphamide, and rituximab or alemtuzumab in treating CLL | 3 | Completed | FCCam, 90%/19.2%; FCR, 91%/33.75% | NCT00564512 | |
Subcutaneous alemtuzumab, bendamustine | Relapsed or refractory CLL | Bendamustine and subcutaneous alemtuzumab in relapsed or refractory chronic lymphocytic leukemia patients | 1/2 | Completed | 68%/24% | NA | |
Alemtuzumab, rituximab, pentostatin | Relapsed or refractory CLL/SLL | Pentostatin, alemtuzumab, and rituximab in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma | 2 | Completed | 56%/28% | NCT00669318 | |
Alemtuzumab, CHOP | PTCL | A phase 2 study of alemtuzumab plus CHOP as frontline chemotherapy for patients with peripheral T-cell lymphoma | 2 | Completed | 80%/65% | NA | |
Alemtuzumab, CHOP | PTCL | GITIL trial of alemtuzumab and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma | 2 | Completed | 75%/71% | NA | |
Alemtuzumab, CHOP | PTCL | Alemtuzumab, MabCampath® with 2-weekly CHOP chemotherapy for mature T-cell non-Hodgkin’s lymphoma | 2 | Completed | 90%/60% | NA | |
Alemtuzumab, CHOP14 vs.CHOP14 | PTCL | Alemtuzumab and CHOP in T-cell Lymphoma | 3 | Completed | ALZ-CHOP, NA/52%; CHOP, NA/42% | NCT00646854 | |
alemtuzumab, CHOP14 vs. CHOP14 | PTCL | Immunotherapy in peripheral T-cell lymphoma—the role of alemtuzumab in addition to dose dense CHOP | 3 | Unknown | ALZ-CHOP, NA/60%; CHOP, NA/43% | NCT00725231 | |
Anti-CD79 antibody | |||||||
polatuzumab vedotin | An anti-CD79b monoclonal antibody conjugated to MMAE | ||||||
Polatuzumab vedotin, rituximab | Relapsed or refractory B-NHLs/CLL | A study of escalating doses of polatuzumab vedotin in participants with relapsed or refractory B-cell non-Hodgkin’s lymphoma and chronic lymphocytic leukemia and polatuzumab vedotin in combination with rituximab in participants with relapsed or refractory B-cell non-Hodgkin’s lymphoma | 1 | Completed | single-agent polatuzumab vedotin: DLBCL, 56%/16%; iNHLs, 47%/20%; MCL, 100%/0%; CLL, 0%/0%; R-pola: 78%/22% | NCT01290549 | |
Pinatuzumab vedotin, obinutuzumab, polatuzumab vedotin, rituximab | Relapsed or refractory DLBCL/FL | A study of pinatuzumab vedotin combined with rituximab or polatuzumab vedotin combined with rituximab or obinutuzumab in participants with relapsed or refractory B-cell non-Hodgkin’s lymphoma | 1/2 | Completed | DLBCL: R-pina, 60%/26%; R-pola, 54%/21%; FL: R-pina, 60%/5%; R-pola, 70%/45% | NCT01691898 | |
Polatuzumab vedotin, rituximab vs. bendamustine, obinutuzumab | Relapsed or refractory DLBCL/FL | A study of polatuzumab vedotin in combination with rituximab or obinutuzumab plus bendamustine in participants with relapsed or refractory follicular or diffuse large B-cell lymphoma | 1/2 | Active, not recruiting | – | NCT02257567 | |
Polatuzumab vedotin, R-CHP vs. R-CHOP | DLBCL | A study comparing the efficacy and safety of polatuzumab vedotin with rituximab-cyclophosphamide, doxorubicin, and prednisone versus rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone in participants with diffuse large B-cell lymphoma | 3 | Recruiting | – | NCT03274492 | – |
Anti-CD19 antibody | |||||||
Inebilizumab | A CD19-targeted humanized monoclonal antibody | ||||||
Inebilizumab | Relapsed or refractory advanced B-NHLs | A phase 1, dose-escalation study of inebilizumab in japanese adult patients with relapsed or refractory advanced B-cell malignancies | 1 | Completed | FL, 82%/55%; DLBCL, 50%/17% | NCT01957579 | |
Inebilizumab, rituximab | Relapsed or refractory B-NHLs | A clinical study using inebilizumab in adult subjects with relapsed or refractory advanced B-cell malignancies | 1/2 | Completed | NA | NCT00983619 | – |
Inebilizumab, bendamustine vs. rituximab, bendamustine | Relapsed or refractory CLL | A phase 2, multicenter, open-label study of inebilizumab in adults with relapsed or refractory chronic lymphocytic leukemia | 2 | Completed | rituximab, bendamustine 59.7%/6.5%; inebilizumab 2mg/kg, bendamustine 52.8%/5.6%; inebilizumab 4mg/kg, bendamustine 63.9%/11.5% | NCT01466153 | – |
Inebilizumab, ICE/DHAP vs. rituximab, ICE/DHAP | Relapsed or refractory DLBCL | A phase 2, multicenter, randomized, open-label study of inebilizumab in adults with relapsed or refractory diffuse large B-cell lymphoma | 2 | Completed | inebilizumab 2mg/kg, ICE/DHAP, 46.2%/NA; inebilizumab 4mg/kg, ICE/DHAP, 43.6%/NA; rituximab, ICE/DHAP, 47.5%/NA | NCT01453205 | – |
Tafasitamab | A novel Fc-engineered, humanized, anti-CD19 antibody with enhanced ADCC | ||||||
Tafasitamab | Relapsed or refractory NHLs | Study of Fc-optimized anti-CD19 antibody tafasitamab to treat non-Hodgkin’s lymphoma | 2 | Active, not recruiting | DLBCL, 26%/6%; FL, 29%/9%; iNHLs, 27%/18% | NCT01685008 | |
Tafasitamab, lenalidomide | Relapsed or refractory DLBCL | A study to evaluate the safety and efficacy of lenalidomide with tafasitamab in patients with relapsed or refractory DLBCL | 2 | Active, not recruiting | 58%/33% | NCT02399085 | |
Tafasitamab, lenalidomide | CLL/SLL, PLL | Phase 2 tafasitamab in combination with lenalidomide for patients with relapsed or refractory CLL/SLL or PLL or older patients with untreated CLL/SLL or PLL | 2 | Active, not recruiting | – | NCT02005289 | – |
Tafasitamab, bendamustine vs. rituximab, bendamustine | Relapsed or refractory DLBCL | A trial to evaluate the efficacy and safety of tafasitamab with bendamustine versus rituximab with bendamustine in adult patients with relapsed or refractory diffuse large B-cell lymphoma | 2/3 | Recruiting | – | NCT02763319 | – |
Coltuximab ravtansine | A CD19-targeted ADC consists of CD19 antibody and a cytotoxic maytansinoid, DM4, which is a potent inhibitor of tubulin polymerization and microtubule assembly | ||||||
Coltuximab ravtansine | Relapsed or refractory DLBCL | Coltuximab ravtansine as single agent in relapsed or refractory diffuse large B-cell lymphoma patients | 2 | Completed | 43.9%/14.6% | NCT01472887 | |
loncastuximab tesirine | An ADC consisting of an anti-CD19 humanized monoclonal antibody conjugated to a cytotoxic, crosslinking agent pyrrolobenzodiazepine dimer | ||||||
loncastuximab tesirine | Relapsed or refractory DLBCL | Study to evaluate the efficacy and safety of ioncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma | 2 | Active, not recruiting | – | NCT03589469 | – |
loncastuximab tesirine | Relapsed or refractory B-NHLs | Study of ioncastuximab tesirine in patients with relapsed or refractory B-cell lineage non-Hodgkin’s lymphoma | 1 | Completed | NA | NCT02669017 | – |
loncastuximab tesirine, ibrutinib | DLBCL/MCL | Safety and antitumor activity study of loncastuximab tesirine plus ibrutinib in diffuse large B-cell or mantle cell lymphoma | 1 | Recruiting | – | NCT03684694 | – |
loncastuximab tesirine, durvalumab | DLBCL/MCL/FL | Safety and antitumor activity study of loncastuximab tesirine and durvalumab in diffuse large B-cell, mantle cell, or follicular lymphoma | 1 | Recruiting | – | NCT03685344 | – |
Anti-CD37 antibody | |||||||
Otlertuzumab | A humanized variant of SMIP-016 built on the ADAPTIR platform | ||||||
Otlertuzumab | Relapsed or refractory NHL/CLL | Phase 1/1b study of otlertuzumab in patients with previously treated CLL or select subtypes of non-Hodgkin’s lymphoma | 1 | Completed | FL, 12.5%/0%; MCL, 0%/0%; WM, 25%/0%; CLL, 23%/0% | NCT00614042 | |
Otlertuzumab, bendamustine vs. bendamustine | Relapsed CLL | Safety and efficacy study of otlertuzumab plus bendamustine vs. bendamustine in relapsed chronic lymphocytic leukemia | 1/2 | Completed | Otlertuzumab and bendamustin, 69%/9%; bendamustin, 39%/3% | NCT01188681 | |
Otlertuzumab, bendamustine, rituximab | Relapsed iNHLs | A study of otlertuzumab in combination with rituximab and bendamustine in subjects with relapsed indolent lymphoma | 1 | Completed | 83%/32% | NCT01317901 | |
IMGN529 | Consisting of an anti-CD37 antibody coupled with the maytansine-derived anti-microtubule agent, DM1 | ||||||
IMGN529 | Relapsed or refractory NHLs/CLL | IMGN529 in treating patients with relapsed or refractory non-Hodgkin’s lymphoma and chronic lymphocytic leukemia | 1 | Completed | DLBCL, 22.2%/5.6%; FL, 7.7%/0%; MCL, 0%/0%; MZL, 0%/0% | NCT01534715 | |
AGS67E | A fully human monoclonal IgG2 antibody conjugated via a protease-cleavable linker to MMAE | ||||||
AGS67E | Relapsed or refractory lymphoid malignancy | A study to evaluate safety, tolerability, and pharmacokinetics of escalating doses of AGS67E given as monotherapy in subjects with refractory or relapsed lymphoid malignancies | 1 | Active, not recruiting | – | NCT02175433 | – |
Betalutin | A novel ARC targeting the CD37 antigen | ||||||
Betalutin | Relapsed or refractory NHLs | A Phase 1/2 study of betalutin for treatment of relapsed non-Hodgkin’s lymphoma | 1/2 | Recruiting | – | NCT01796171 | – |
Betalutin | Relapsed or refractory DLBCL | Study of betalutin for treatment of relapsed or refractory non-Hodgkin’s lymphoma (LYMRIT-37-05) | 1 | Recruiting | – | NCT02658968 | – |
Betalutin, rituximab | Relapsed or refractory FL | Study of safety and efficacy of betalutin and rituximab in patients with FL | 1 | Recruiting | – | NCT03806179 | – |
Anti-CCR4 | |||||||
Mogamulizumab | A defucosylated humanized monoclonal antibody directed against CCR4 | ||||||
Mogamulizumab | ATLL | Phase 2 study of KW-0761 in subjects with CCR4+ adult T-cell leukemia/lymphoma | 2 | Completed | 50%/31% | NCT00920790 | |
Mogamulizumab, mLSG15 vs. mLSG15 | ATLL | Multicenter, randomized, open-label, parallel-group study to compare mLSG15 plus mogamulizumab to mLSG15 | 2 | Completed | Mogamulizumab, mLSG15, 86%/52%; mLSG15, 75%/33% | NCT01173887 | |
Mogamulizumab | PTCL | Safety study to evaluate monoclonal antibody mogamulizumab in subjects with peripheral T-cell lymphoma | 1/2 | Completed | 36.8%/7.9% | NCT00888927 | |
Mogamulizumab | PTCL | Study of mogamulizumab in subjects with CCR4+ T-cell lymphoma | 2 | Completed | 35%/14% | NCT01192984 | |
Mogamulizumab vs. vorinostat | Relapsed or refractory CTCL | Study of mogamulizumab versus vorinostat in relapsed or refractory CTCL | 3 | Active, not recruiting | Mogamulizumab, 28%/3%; vorinostat, 5%/0% | NCT01728805 | |
Anti-CD25 antibody | |||||||
90Y-daclizumab | A radiolabeled anti-CD25 antibody | ||||||
90Y-daclizumab | HL/NHLs | 90Y-Daclizumab to treat Hodgkin’s disease, non-Hodgkin’s lymphoma and lymphoid leukemia | 1/2 | Completed | Relapsed HL, 50%/30% | NCT00001575 | |
90Y-basiliximab | A radiolabeled anti-CD25 antibody | ||||||
90Y-basiliximab, BEAM | Relapsed or refractory HL | Radiolabeled monoclonal antibody therapy and combination chemotherapy before stem cell transplant in treating patients with primary refractory or relapsed Hodgkin’s lymphoma | 1 | Active, not recruiting | – | NCT01476839 | – |
90Y-basiliximab, BEAM | Mature T-NHLs | 90Y-basiliximab and combination chemotherapy before stem cell transplant in treating patients with mature T-cell non-Hodgkin’s lymphoma | 1 | Recruiting | – | NCT02342782 | – |
Camidanlumab tesitine | A CD25 antibody-drug conjugate | ||||||
Camidanlumab tesitine | Relapsed or refractory HL/NHLs | Study of camidanlumab tesitine in patients with relapsed or refractory Hodgkin’s and non-Hodgkin’s lymphoma | 1 | Completed | NA | NCT02432235 | – |
Anti-CD38 antibody | |||||||
Daratumumab | An anti-CD38 monoclonal antibody | ||||||
Daratumumab | Relapsed or refractory NKTCL, nasal type | A study to assess the clinical efficacy and safety of daratumumab in participants with relapsed or refractory NK/T-cell lymphoma, nasal type | 2 | Active, not recruiting | 35.7%/0% | NCT02927925 | |
Anti-CD40 antibody | |||||||
Dacetuzumab | A humanized IgG1 monoclonal antibody targeting CD40 | ||||||
Dacetuzumab | NHL | A safety study of dacetuzumab in patients with non-Hodgkin’s lymphoma | 1 | Completed | 12%/2% | NCT00103779 | |
Dacetuzumab | Relapsed DLBCL | Study of dacetuzumab in patients with relapsed diffuse large B-cell lymphoma | 2 | Completed | 9%/4% | NCT00435916 | |
Dacetuzumab, R-ICE vs. placebo, R-ICE | Relapsed DLBCL | A randomized phase 2 placebo-controlled study of R-ICE chemotherapy with and without dacetuzumab for patients with DLBCL | 2 | Terminated | Dacetuzumab, R-ICE, 66%/33%; placebo, R-ICE, 64%/36% | NCT00529503 | |
Anti-CD74 antibody | |||||||
milatuzumab | A humanized antibody against CD74 | ||||||
Milatuzumab, veltuzumab | Relapsed or refractory B-NHLs | Veltuzumab and milatuzumab in treating patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma | 1/2 | Completed | FL, 33%/7%; DLBCL, 0%/0%; MCL, 17%/0%; MZL, 100%/50%; WM, 0%/0% | NCT00989586 | |
Anti-CD80 antibody | |||||||
Galiximab | An anti-CD80 monoclonal antibody | ||||||
Galiximab | Relapsed or refractory HL | Galiximab in treating patients with relapsed or refractory Hodgkin’s lymphoma | 2 | Completed | 10.3%/NA | NCT00516217 | – |
Galiximab | Relapsed or refractory FL | Phase 1/2 study of galiximab for relapsed or refractory follicular lymphoma | 1/2 | Completed | 11%/6% | – | |
Galiximab, rituximab | Relapsed or refractory FL | Safety and efficacy of galiximab in combination with rituxan in the treatment of non-Hodgkin’s lymphoma | 1/2 | Completed | 66%/19% | NCT00048555 | |
Anti-CD158k antibody | |||||||
IPH4102 | An anti-CD158k monoclonal antibody | ||||||
IPH4102 | Relapsed or refractory CTCL | Study of IPH4102 in patients with relapsed or refractory cutaneous T-cell lymphoma | 1 | Active, not recruiting | 45%/0% | NCT02593045 | |
IPH4102 vs. IPH4102, gemcitabine, oxaliplatin | Advanced T-NHLs | IPH4102 alone or in combination with chemotherapy in patients with advanced T-cell lymphoma | 2 | Recruiting | – | NCT03902184 | – |
Bispecific T cell Engager | |||||||
Blinatumomab | A CD19/CD3 Bispecific T cell Engager | ||||||
Blinatumomab | Relapsed NHLs | Safety study of the bispecific T-cell engager blinatumomab in patients with relapsed NHLs | 1 | Completed | DLBCL, 55%/36%; MCL, 71%/43%; FL, 80%/40% | NCT00274742 | |
Blinatumomab | Relapsed or refractory DLBCL | Clinical study with blinatumomab in patients with relapsed or refractory diffuse large B-cell lymphoma | 2 | Completed | 43%/19% | NCT01741792 | |
Blinatumomab | Relapsed or refractory aggressive B-NHLs | Study to evaluate safety and efficacy of blinatumomab in subjects with relapsed or refractory aggressive B-cell NHL | 2 | Active, not recruiting | – | NCT02910063 | – |
Mosunetuzumab | A CD20/CD3 Bispecific T cell Engager | ||||||
Mosunetuzumab | DLBCL | A trial of mosunetuzumab as consolidation therapy in participants with diffuse large B-cell lymphoma following first-line immunochemotherapy and as therapy in participants with previously untreated diffuse large B-cell lymphoma who are unable to tolerate full-dose chemotherapy | 1/2 | Recruiting | – | NCT03677154 | – |
Mosunetuzumab, polatuzumab vedotin | B-NHLs | A study to evaluate the safety and efficacy of mosunetuzumab in combination with polatuzumab vedotin in B-cell non-Hodgkin’s lymphoma | 1 | Recruiting | – | NCT03671018 | – |
Mosunetuzumab, polatuzumab vedotin, CHP vs.mosunetuzumab, CHOP | B-NHLs | A phase 1/2 study investigating the safety, tolerability, pharmacokinetics, and efficacy of mosunetuzumab in combination With CHOP or CHP-polatuzumab vedotin in participants With B-cell non-Hodgkin’s lymphoma | 1/2 | Recruiting | – | NCT03677141 | – |
RO7082859 | A CD20/CD3 Bispecific T cell Engager | ||||||
RO7082859, obinutuzumab | Relapsed or refractory B-NHLs | A dose escalation study of RO7082859 as a single agent and in combination with obinutuzumab, administered after a fixed, single pre-treatment dose of obinutuzumab in participants with relapsed or refractory B-cell non-Hodgkin’s lymphoma | 1 | Recruiting | – | NCT03075696 | – |
RO7082859, atezolizumab, obinutuzumab | Relapsed or refractory B-NHLs | An open-label phase 1b study of RO7082859 and atezolizumab in adult patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma | 1 | Recruiting | – | NCT03533283 | – |
RO7082859, obinutuzumab/rituximab, CHOP | B-NHLs | A study of RO7082859 in combination with rituximab or obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in participants with non-Hodgkin’s lymphomas | 1 | Recruiting | – | NCT03467373 | – |
REGN1979 | A CD20/CD3 Bispecific T cell Engager | ||||||
REGN1979 | Relapsed or refractory FL | Assess the antitumor activity and safety of REGN1979 in patients with relapsed or refractory follicular lymphoma | 2 | Recruiting | – | NCT03888105 | – |
REGN1979 | B-NHLs | A phase 1 study to investigate the safety and tolerability of REGN1979 in patients With CD20+ B-cell malignancies | 1 | Recruiting | – | NCT02290951 | – |
REGN1979, REGN2810 | B-NHLs | Study of REGN2810 and REGN1979 in patients with lymphoma | 1 | Recruiting | – | NCT02651662 | – |
XmAb13676 | A CD20/CD3 Bispecific T cell Engager | ||||||
XmAb13676 | B-NHLs, CLL/SLL | Study to evaluate safety and tolerability of XmAb13676 in patients with CD20− expressing hematologic malignancies | 1 | Recruiting | – | NCT02924402 | – |
